DE69716414D1 - Benzoxazine zur erhöhung der synaptischen reaktionen - Google Patents

Benzoxazine zur erhöhung der synaptischen reaktionen

Info

Publication number
DE69716414D1
DE69716414D1 DE69716414T DE69716414T DE69716414D1 DE 69716414 D1 DE69716414 D1 DE 69716414D1 DE 69716414 T DE69716414 T DE 69716414T DE 69716414 T DE69716414 T DE 69716414T DE 69716414 D1 DE69716414 D1 DE 69716414D1
Authority
DE
Germany
Prior art keywords
compounds
subjects
ampa receptors
benzoxazine
reactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69716414T
Other languages
English (en)
Other versions
DE69716414T2 (de
Inventor
A Rogers
S Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE69716414D1 publication Critical patent/DE69716414D1/de
Application granted granted Critical
Publication of DE69716414T2 publication Critical patent/DE69716414T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69716414T 1996-04-03 1997-03-28 Benzoxazine zur erhöhung der synaptischen reaktionen Expired - Lifetime DE69716414T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/624,335 US5736543A (en) 1996-04-03 1996-04-03 Benzoxazines for enhancing synaptic response
PCT/US1997/005184 WO1997036907A1 (en) 1996-04-03 1997-03-28 Benzoxazines for enhancing synaptic response

Publications (2)

Publication Number Publication Date
DE69716414D1 true DE69716414D1 (de) 2002-11-21
DE69716414T2 DE69716414T2 (de) 2003-06-12

Family

ID=24501596

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716414T Expired - Lifetime DE69716414T2 (de) 1996-04-03 1997-03-28 Benzoxazine zur erhöhung der synaptischen reaktionen

Country Status (10)

Country Link
US (2) US5736543A (de)
EP (1) EP0891365B1 (de)
JP (1) JP3170294B2 (de)
AT (1) ATE226206T1 (de)
AU (1) AU708212B2 (de)
DE (1) DE69716414T2 (de)
DK (1) DK0891365T3 (de)
ES (1) ES2185932T3 (de)
NZ (1) NZ331992A (de)
WO (1) WO1997036907A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721936B2 (en) * 1996-04-03 2000-07-20 Regents Of The University Of California, The Benzoxazines for enhancing synaptic response
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
AU745641B2 (en) * 1997-10-27 2002-03-28 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6011991A (en) * 1998-12-07 2000-01-04 Technology Patents, Llc Communication system and method including brain wave analysis and/or use of brain activity
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
JP4435562B2 (ja) 2001-06-14 2010-03-17 ナームローゼ・フエンノートチヤツプ・オルガノン （ピリド／チエノ）−［ｆ］−オキサゼピン−５−オン誘導体
EP1448537A4 (de) * 2001-11-26 2005-05-04 Cortex Pharma Inc Carbonylbenzoxazinverbindungen zur verstärkung der glutamatergen synaptischen reaktionen
KR20050093856A (ko) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
NZ540468A (en) 2003-01-13 2008-03-28 Univ California Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8173644B2 (en) * 2007-01-03 2012-05-08 Les Laboratoires Servier 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
KR20090098999A (ko) * 2007-01-03 2009-09-18 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 3-치환된-[1,2,3]벤조트리아지논 화합물
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
MX2009009937A (es) * 2007-03-23 2009-09-24 Univ California Tratamiento de la disfuncion sexual femenina mediante compuestos que modulan de manera positiva los receptores de glutamato tipo ampa.
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
CA2695742C (en) * 2007-08-10 2012-11-27 Rudolf Mueller Bicyclic amides for enhancing glutamatergic synaptic responses
US8071914B2 (en) 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
EP2801377B1 (de) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel enthaltend Zellen zur lokalen Freisetzung von Wachstumsfaktoren zur Rückgewinnung der Bewegungsfähigkeit nach einem Schlaganfall
WO2014117089A1 (en) 2013-01-25 2014-07-31 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
WO2019133997A1 (en) 2017-12-31 2019-07-04 Neuroenhancement Lab, LLC System and method for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257396A (en) * 1962-06-11 1966-06-21 Geigy Chem Corp Certain 1, 3-benzoxazinone derivatives
PT1156043E (pt) * 1992-07-24 2004-03-31 Univ California Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response

Also Published As

Publication number Publication date
EP0891365B1 (de) 2002-10-16
DK0891365T3 (da) 2003-02-10
ATE226206T1 (de) 2002-11-15
JP2000503664A (ja) 2000-03-28
ES2185932T3 (es) 2003-05-01
US5736543A (en) 1998-04-07
JP3170294B2 (ja) 2001-05-28
DE69716414T2 (de) 2003-06-12
AU708212B2 (en) 1999-07-29
AU2427497A (en) 1997-10-22
NZ331992A (en) 1999-02-25
WO1997036907A1 (en) 1997-10-09
US5962447A (en) 1999-10-05
EP0891365A1 (de) 1999-01-20

Similar Documents

Publication Publication Date Title
DE69716414D1 (de) Benzoxazine zur erhöhung der synaptischen reaktionen
PT839134E (pt) Benzoilpiperidinas/pirrolidinas para melhoramento da resposta sinaptica
CA2138533A1 (en) Drugs that enhance synaptic responses mediated by ampa receptors
PL341427A1 (en) Benzoxazinic compounds for enhancing sybaptic response
ATE526020T1 (de) Gesteigertes kognitives training
DE69834590D1 (de) Benzofurazanderivate und deren verwendung zur verbesserung glutaminerger synaptischer antworten
DE69910552D1 (de) Acylbenzoxazine zur erhöhung der synaptischen reaktion(en)
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted